The 'Mighty Mouse' Model in Experimental Cardiac Transplantation

Abstract

Heterotopic Vascularized Cardiac Grafts in Rodents Heterotopic transplantation was used as early as the 1940's and 50's in large animals but it wasn't until work by Abbott et al. in 1964 that the heterotopic heart transplantation (HHTX) was perfomed in rodents; the authors used rats and utilized end-to-end anastomosis of the donor thoracic aorta to the recipient abdominal aorta and donor pulmonary artery to recipient inferior vena cava (IVC) (10). Abbott's procedure resulted in restricted blood flow to the lower extremities and consequently, paraparesis and paraplegia (1). This procedure was revised by Ono and Lindsey to allow for greater blood flow to the lower extremities and employed end-to-side anastomoses of the donor vessels to the recipient aorta and IVC, resulting in 90% graft and recipient survival (11). Heterotopic cervical transplantation was performed in rats in 1971 (12) and required the anastomosis of the re

An alternative technique of arterial anastomosis in mouse heart transplantation

“…With the extensive development of organ transplantation, MHT has become an important tool for the study of anastomosis technique and transplantation . The main method of arterial anastomosis is CS method, which has a simple operation process and can save the operation time .…”

“…With the extensive development of organ transplantation, MHT has become an important tool for the study of anastomosis technique and transplantation. 8 The main method of arterial anastomosis is CS method, which has a simple operation process and can save the operation time. [9][10][11][12] However, in the process of CS method, the exposure of anastomotic site is getting smaller, which cause the edge of the artery is difficult to determine at the last 1-2 stitches.…”

The unnoticed truth: Patients on the heart transplantation waiting list are becoming cachexic

“…As the number of hearts available for transplantation is very limited, rejection is a great concern and the risk of tissue rejection would never be eliminated for a recipient's lifetime. Because of this, recipients are required to use lifelong immunosuppressive medications and are continuously monitored [7,8].…”

Induction of substantial myocardial regeneration by an active fraction of the Chinese herb Rosa laevigata Michx

“…Population-based clinical studies have demonstrated that although current advanced treatment modalities, including beta-adrenoceptor blockers, diuretics, and angiotensin-converting enzyme inhibitors, as well as surgical intervention procedures and mechanical assistance devices, are effective in improving symptoms and other outcomes in patients, these therapies restore neither the pathologic changes nor the functional performance of the damaged heart and have problematic complications [ 12 , 13 ]. Heart transplantation may be an effective treatment for end-stage heart failure; the applicability of this procedure, however, is seriously limited by the availability of donor hearts and the concurrent immunorejection upon transplantation [ 14 , 15 ]. Therefore, CHD remains the most prevalent cause of death, and the structural and functional restoration of the damaged heart remains a formidable challenge.…”